Loading…
MBIO
Mustang Bio Inc
NASDAQ· Healthcare· Biotechnology· CUSIP 62818Q302
$0.54-2.27%Price as of Aug 29, 18:32 UTC · updated once a day, after the close
Key metrics
- Market cap
- $4.07M
- P/E
- —
- Forward P/E
- —
- P/B
- 0.5x
- Dividend yield
- —
- Payout
- —
- EPS
- -$0.42
- ROE
- -58.12%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- 2.05
- 52-week high
- $1.85
- 52-week low
- $0.53
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -100.0% over 5Y.
today you would have $0.26▼ -100.0%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $0.98 | $8.85 | $67.50 | $296.25 | |
| P/B | 1.3x | 0.8x | — | 555.8x | 1.3x |
| EPS | -$0.39 | -$38.57 | -$299.95 | -$562.50 | |
| ROE | -167.54% | -20.16% | — | -41952.85% | -167.54% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| TCRTAlaunos Therapeutics, Inc. | $1.61 | — | 3.0x | — | -185.95% | $4.08M |
| RDHLRedHill Biopharma Ltd. | $0.66 | — | 0.8x | — | — | $4.02M |
| REVBRevelation Biosciences Inc | $1.05 | 0.0x | 0.4x | — | -154.77% | $4.18M |
| JAGXJaguar Health, Inc. | $0.81 |
About the company
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134. It has a license agreement with city of hope national medical center and nationwide children's hospital. Mustang Bio, Inc. was incorporated in 2015 and is headquartered in Waltham, Massachusetts.
- 4
- Waltham, United States
Company description provided by Yahoo Finance.